文献速递胸部肿瘤放疗

接受放化疗与免疫检查点抑制剂治疗的非小细胞肺癌患者的放射性肺炎:一项回顾性研究

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
PubMed 文献 · Radiat Oncol · 2021-12-04

该回顾性研究纳入106例非小细胞肺癌患者,评估计划靶区体积、平均肺剂量及不同阈值受照肺体积(VD)对放射性肺炎的预测作用。主要终点为≥2级放射性肺炎。结果显示,同步放化疗后接受免疫检查点抑制剂治疗与放射性肺炎发生相关(p=0.043),且高剂量受照肺体积可能与该风险相关。

要点

  • 同步放化疗后使用ICI与≥2级放射性肺炎发生相关(p=0.043)。
  • 单变量分析中MLD、V20、V30、V40均与放射性肺炎发生相关。
  • 非ICI组仅V20为显著危险因素,ICI组MLD、V30、V40为显著危险因素。

核心结论

  • 根治性同步放化疗后接受ICI治疗的患者更易发生≥2级放射性肺炎,这可能与高剂量受照肺体积有关。
  • 作者认为,对于非小细胞肺癌患者应仔细考虑多个因素。

研究设计与样本

  • 回顾性研究,纳入106例非小细胞肺癌患者,评估计划靶区体积、平均肺剂量及不同阈值受照肺体积(VD)。
  • 主要终点为≥2级放射性肺炎,并评估毒性。

主要发现

  • 同步放化疗后51/106例患者接受ICI治疗。
  • 中位随访期11.5个月(范围3.0-28.2),47例(44.3%)发生≥2级放射性肺炎,其中ICI组27例、非ICI组20例。
  • 临床因素中仅使用ICI与放射性肺炎相关(p=0.043)。
  • 单变量分析中,MLD(HR 2.3,p=0.009)、V20(HR 2.9,p=0.007)、V30(HR 2.3,p=0.004)、V40(HR 2.5,p=0.001)与肺炎发生相关。
  • 非ICI组仅V20为显著危险因素,ICI组MLD、V30、V40为显著危险因素;ICI组生存率和局部控制率优于非ICI组但无统计学显著性。

关键数值与推荐

  • ICI使用与放射性肺炎相关(p=0.043)。
  • MLD的HR为2.3(p=0.009),V20的HR为2.9(p=0.007),V30的HR为2.3(p=0.004),V40的HR为2.5(p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy has been administered to many patients with non-small-cell lung cancer (NSCLC). However, only few studies have examined toxicity in patients receiving an immune checkpoint inhibitor (ICI) after concurrent chemoradiotherapy (CCRT). Therefore, we performed a retrospective study to determine factors that predict radiation pneumonitis (RP) in these patients. METHODS: We evaluated the size of the planning target volume, mean lung dose (MLD), and the lung volume receiving more than a threshold radiation dose (VD) in 106 patients. The primary endpoint was RP ≥ grade 2, and toxicity was evaluated. RESULTS: After CCRT, 51/106 patients were treated with ICI. The median follow-up period was 11.5 months (range, 3.0-28.2), and RP ≥ grade 2 occurred in 47 (44.3%) patients: 27 and 20 in the ICI and non-ICI groups, respectively. Among the clinical factors, only the use of ICI was associated with RP (p = 0.043). Four dosimetric variables (MLD, V20, V30, and V40) had prognostic significance in univariate analysis for occurrence of pneumonitis (hazard ratio, p-value; MLD: 2.3, 0.009; V20: 2.9, 0.007; V30: 2.3, 0.004; V40: 2.5, 0.001). Only V20 was a significant risk factor in the non-ICI group, and MLD, V30, and V40 were significant risk factors in the ICI group. The survival and local control rates were superior in the ICI group than in the non-ICI group, but no significance was observed. CONCLUSIONS: Patients receiving ICI after definitive CCRT were more likely to develop RP, which may be related to the lung volume receiving high-dose radiation. Therefore, several factors should be carefully considered for patients with NSCLC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jang JY, Kim SS, Song SY, et al. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study. Radiat Oncol. 2021. PMID: 34863244. doi:10.1186/s13014-021-01930-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。